Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Pfizer (PFE) vs. AbbVie (ABBV)

By Keith Speights - Dec 10, 2017 at 9:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

They're two of the biggest of big pharma stocks. But which is the better long-term pick?

For Pfizer (PFE -0.23%), 2017 so far has looked better than the past couple of years in terms of stock performance. However, the stock's 9% year-to-date gain isn't anything to jump up and down about. AbbVie's (ABBV 0.42%) performance, on the other hand, warrants plenty of jumping. The stock is up more than 50% and is on track for its best yearly gain ever.

All that's water under the bridge, though. What really matters for investors is how stocks will perform in the future. Both Pfizer and AbbVie have solid potential, but which is the better choice for long-term investors? Here's how the two big pharma stocks compare.

Two white doors with one closed and one open

Image source: Getty Images.

Growth

Pfizer's current growth stems in large part from five products: blood thinner Eliquis, breast cancer drug Ibrance, nerve pain drug Lyrica, rheumatoid arthritis drug Xeljanz, and prostate cancer drug Xtandi. However, the company faces headwinds for many of its products that have either lost exclusivity or soon will do so. 

The drugmaker's pipeline includes an impressive 95 clinical programs. Pfizer awaits regulatory approval for 10 of those, with another 28 programs in late-stage testing. Some of these programs are pursuing additional indications for already-approved drugs, but others, such as pain drug tanezumab and breast cancer drug talazoparib, haven't hit the market yet. 

AbbVie, meanwhile, has relied on its powerhouse autoimmune disease drug Humira to drive growth in the past, and the company expects continued, albeit slowing sales growth for the drug. AbbVie also has cancer drug Imbruvica in its lineup, which is on track to generate sales of $2.5 billion this year -- up more than 40% year over year. In addition, it recently launched hepatitis C drug Mavyret, which could become another blockbuster for AbbVie. 

Although AbbVie's pipeline doesn't match Pfizer's quantity of drugs in development, quality is a different story. Earlier this year, market researcher EvaluatePharma ranked AbbVie's pipeline as the third best in the biopharmaceutical industry. Two especially promising candidates for AbbVie are autoimmune disease drug upadacitinib and cancer drug Rova T.

Wall Street analysts project that Pfizer will increase annual earnings by around 6% in the coming years, an improvement over the drugmaker's recent growth. Analysts think that AbbVie will grow its earnings by 15% annually.

Valuation

Both of these pharma stocks appear to be attractively valued. Pfizer shares currently trade at 22 times trailing-12-month earnings and less than 13 times expected earnings. AbbVie's trailing earnings multiple stands at 23, with a forward earnings multiple of 14.

Dividend

Investors also have a lot to like about both companies' dividends. Pfizer's dividend yields 3.6% right now, while AbbVie's yield is just under 3%. Pfizer currently uses around 78% of its earnings to fund its dividend program. AbbVie's dividend payout ratio is 60%. Neither company's dividend appears to be in jeopardy.

AbbVie claims the better track record of dividend hikes. Since being spun off from parent Abbott Labs in 2013, the company's dividend has increased by nearly 78%. Pfizer has also increased its dividend, with growth of 33% over the last five years.

Better buy

I like both of these stocks. In fact, I own shares of both of them. Pfizer has the higher dividend yield, which is a big plus. It also has an advantage in valuation based on earnings multiples.

However, AbbVie's growth prospects are much higher than Pfizer's. Factoring that potential growth in, AbbVie is the more attractively valued stock. And while its yield is lower than Pfizer's, that's mainly a factor of its tremendous stock performance this year.

Of course, the dynamics could change for either of these companies. Both Pfizer and AbbVie have made key acquisitions in recent years and could do more in the future. I'd bet on both of them doing more deals in 2018. Also, Pfizer is considering spinning off or selling its consumer healthcare business. Shareholders have enjoyed nice gains as a result of the company's spinoff of its animal health business, now known as Zoetis. It's possible that they could have similar prospects if Pfizer chooses to spin off the consumer unit.

Still, I don't think any changes resulting from acquisitions, divestitures, or spinoffs would fundamentally alter the decision before us right now. AbbVie is the better buy. Some stocks offer only growth, attractive valuation, or solid income, and not all of them. AbbVie, on the other hand, is strong on all three counts, making it the best big pharma stock on the market in my view.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$153.80 (0.42%) $0.64
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.31 (-0.23%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.